What are kratom’s uses and risks and how are states regulating it?

The rise of peptide usage in the United States has reached a critical juncture, driven by increasing consumer interest in compounds marketed for recovery, sleep improvement, performance enhancement, metabolic health, and longevity. These substances, which consist of short chains of amino acids, have gained popularity largely due to their purported health benefits, often promoted through online platforms and informal networks. However, many users acquire these peptides outside of traditional healthcare systems, bypassing medical supervision, quality control measures, and precise dosing guidelines. This trend has raised concerns among public health officials and regulators, who are grappling with how best to address the growing demand without stifling innovation or driving usage further into unregulated channels. At the center of this discussion is the U.S. Food and Drug Administration (FDA), where Kyle Diamantas now serves as acting commissioner. With his leadership, the agency faces a pivotal moment in shaping policy around peptides. Instead of adopting either a complete ban or allowing uncontrolled proliferation, the FDA is exploring a nuanced approach that seeks to balance accessibility with safety. A key step in this process involves the Pharmacy Compounding Advisory Committee, which is set to convene on July 23–24 to evaluate whether specific peptides should be reintroduced onto the list of substances eligible for compounding by licensed 503A pharmacies. A follow-up session is scheduled for early 2027, providing an opportunity to refine and implement new regulations. Peptides are not a uniform category. Some, such as insulin and GLP-1 agonists like semaglutide, represent groundbreaking advancements in medicine, having undergone extensive testing and received FDA approval. These drugs are routinely prescribed and have demonstrated significant therapeutic value. In contrast, other peptides—often marketed for wellness and performance—lack comparable scientific validation and regulatory oversight. Currently, these compounds exist in a legal gray area, frequently labeled as “research use only” or “not for human consumption.” Their production lacks standardized quality assurance, and their use typically occurs without clinical guidance, raising serious safety concerns. Prohibiting access to these gray-zone peptides outright is unlikely to curb demand, according to experts. Historical patterns indicate that restrictive policies tend to shift consumer behavior toward riskier, less regulated alternatives. The primary threat to public health, therefore, stems not from medically supervised use but from the prevalence of unverified and potentially harmful products circulating in black and gray markets. Addressing this issue requires a pragmatic strategy that acknowledges current realities rather than attempting to ignore them. One proposed solution involves creating a structured framework that allows select, commonly used peptides to be produced and dispensed under the supervision of licensed pharmacies adhering to federal and state standards for quality, sourcing, and sterility. Under this model, patients would gain access to these compounds only after consultation with a qualified clinician. Such professionals would assess individual needs and risks, provide comprehensive information based on available studies, animal data, and real-world experiences, and ensure continuous monitoring and documentation of outcomes. This approach aims to guide patients responsibly while generating valuable real-world data that could inform future regulatory decisions. The proposed system also emphasizes transparency and accountability. Compounded medications would include explicit disclaimers, and clinicians would be required to record informed consent from patients. This framework does not intend to replace formal FDA approval processes but rather complements them by offering a pathway for responsible use within a controlled environment. By doing so, it acknowledges the complexity of the situation and seeks to align regulatory efforts with the actual behaviors and preferences of consumers. As awareness of peptides continues to grow, many individuals are approaching healthcare providers with questions about their potential benefits. Doctors increasingly find themselves navigating discussions about these substances, often lacking sufficient tools or guidance to address patient inquiries effectively. Implementing a structured regulatory approach could empower clinicians to provide more informed responses while ensuring that patients receive safe and appropriate care. For those seeking solutions to challenges related to recovery, sleep, metabolism, and aging, clinician-supervised peptides may hold promise—if approached with careful study and intelligent regulation.